NAVIDEA BIOPHARMACEUTICALS I (NAVB) Stock Analyst Ratings
USA - NYSEARCA:NAVB - US63937X2027 - Common Stock
0.0779 USD
0 (-2.99%)
ChartMill assigns a Buy % Consensus number of 83% to NAVB. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 5.1. This target is 6446.85% above the current price.
NAVB was analyzed by 7 analysts. The buy percentage consensus is at 83. So analysts seem to be very confident about NAVB.
In the previous month the buy percentage consensus was at a similar level.
NAVB was analyzed by 7 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
NAVIDEA BIOPHARMACEUTICALS I / NAVB FAQ
Can you provide the average price target for NAVIDEA BIOPHARMACEUTICALS I stock?
7 analysts have analysed NAVB and the average price target is 5.1 USD. This implies a price increase of 6446.85% is expected in the next year compared to the current price of 0.0779.
How do analysts rate NAVIDEA BIOPHARMACEUTICALS I (NAVB)?
The consensus rating for NAVIDEA BIOPHARMACEUTICALS I (NAVB) is 82.8571 / 100 . This indicates that analysts generally have a positive outlook on the stock.
Can you provide the analyst count for NAVIDEA BIOPHARMACEUTICALS I stock?
The number of analysts covering NAVIDEA BIOPHARMACEUTICALS I (NAVB) is 7.